Delgocitinib

INN (International Nonproprietary Name)

🇺🇸 Also approved in the US (FDA)

ANZUPGO — LEO PHARMA AS, approved 2026-06-30 (NDA219155).

Most reported adverse events (US / FAERS)

165 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

product use in unapproved indication

42

pruritus

19

dermatitis

14

erythema

14

Medicines containing this active substance

1 medicines

Anzupgo

Authorised

🇺🇸 Also approved in the US (FDA)

ANZUPGO — LEO PHARMA AS, approved 2026-06-30 (NDA219155).

Most reported adverse events (US / FAERS)

165 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

product use in unapproved indication

42

pruritus

19

dermatitis

14

erythema

14

dermatitis atopic

12

drug ineffective

12

rash

9

erythema multiforme

8

dry skin

6

skin burning sensation

6

burning sensation

5

cellulitis

5

off label use

5

condition aggravated

4

drug ineffective for unapproved indication

4